Important Biotech Catalysts For September 15, 2022 – End Of The Day Summary – Kymera Therapeutics (NASDAQ:KYMR), Edwards Lifesciences (NYSE:EW), Alnylam Pharmaceuticals (NASDAQ:ALNY), Candel Therapeutics (NASDAQ:CADL), Incyte (NASDAQ:INCY), Jasper Therapeutics (NASDAQ:JSPR), Celsion (NASDAQ:CLSN), Lipocine (NASDAQ:LPCN), Regeneron Pharmaceuticals (NASDAQ:REGN), Tenax Therapeutics (NASDAQ:TENX), Omeros (NASDAQ:OMER), Pfizer (NYSE:PFE)
[ad_1] Pfizer PFE announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals…
Syros Pharmaceuticals (NASDAQ:SYRS), Oramed Pharmaceuticals (NASDAQ:ORMP), Vaxxinity (NASDAQ:VAXX), Genfit (NASDAQ:GNFT), Akouos (NASDAQ:AKUS), Conformis (NASDAQ:CFMS), Merck & Co (NYSE:MRK), Akero Therapeutics (NASDAQ:AKRO), Cidara Therapeutics (NASDAQ:CDTX), aTyr Pharma (NASDAQ:LIFE), Lyra Therapeutics (NASDAQ:LYRA) – Important Biotech Catalysts For September 13, 2022 – End Of The Day Summary
[ad_1] Akero Therapeutics AKRO revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with…
Lyra Therapeutics (NASDAQ:LYRA) – Lyra’s Mid-Stage Chronic Rhinosinusitis Candidate Study Progressed, Shares Fall
[ad_1] Lyra Therapeutics LYRA advanced into its Part 2 of the Phase 2 BEACON clinical trial of LYR-220 in adults with chronic rhinosinusitis (CRS) who have had a prior sinus…
Adamis Pharmaceuticals (NASDAQ:ADMP) – Adamis Achieves Enrolment Target In Mid-Stage Covid-19 Study, Awaits Data Safety Monitoring Board Review Later This Month
[ad_1] Adamis Pharmaceuticals ADMP announced that it has reached the initial planned enrollment target in the ongoing U.S. Phase 2/3 clinical trial investigating Tempol as a treatment for COVID-19. The Phase…
Spectrum Pharmaceuticals (NASDAQ:SPPI) – Spectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022
[ad_1] The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ SPPI lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. ROLVEDON…